Source link : https://www.newshealth.biz/health-news/new-drug-effective-for-tenosynovial-giant-cell-tumors-and-with-no-liver-concerns/
CHICAGO — An oral investigational agent effectively shrank tenosynovial giant cell tumors (TGCTs) while demonstrating functional and symptomatic benefits for patients, the phase III MOTION trial showed. In 83 patients with the non-malignant tumors for whom surgery would potentially worsen functional limitations or cause severe morbidity, the study’s primary endpoint showed a 40% overall response […]
Author : News Health
Publish date : 2024-06-04 15:50:20
Copyright for syndicated content belongs to the linked Source.
Categories